Experienced in Intraductal Papilloma

Dr. Raymond Brig

Hematology Oncology
1400 Dowell Springs Road, Suite 200, 
Knoxville, TN 
Experienced in Intraductal Papilloma
1400 Dowell Springs Road, Suite 200, 
Knoxville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raymond Brig is a Hematologist Oncology provider in Knoxville, Tennessee. Dr. Brig is rated as an Experienced provider by MediFind in the treatment of Intraductal Papilloma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in KY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

1400 Dowell Springs Road, Suite 200, Knoxville, TN 37909

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

2 Total Publications

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Journal: Breast cancer (Tokyo, Japan)
Published: March 14, 2024
Similar Doctors
Distinguished in Intraductal Papilloma
Dr. Daniel M. Ibach
Hematology Oncology | Hematology | Oncology
Distinguished in Intraductal Papilloma
Dr. Daniel M. Ibach
Hematology Oncology | Hematology | Oncology

Tennessee Cancer Specialists PLLC

9957 Sherrill Blvd, 
Knoxville, TN 
 (5.8 miles away)
865-693-2244
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Ibach is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Ibach is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Iron Deficiency Anemia, Breast Cancer, and Bone Marrow Aspiration. Dr. Ibach is currently accepting new patients.

Advanced in Intraductal Papilloma
Dr. Susan M. Newman
Hematology Oncology | Hematology | Oncology
Advanced in Intraductal Papilloma
Dr. Susan M. Newman
Hematology Oncology | Hematology | Oncology

University Health System, Inc.

1926 Alcoa Hwy 410, 
Knoxville, TN 
 (4.4 miles away)
865-544-9218
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Susan Newman is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Newman is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Non-Hodgkin Lymphoma, Astrocytoma, and Tissue Biopsy. Dr. Newman is currently accepting new patients.

Advanced in Intraductal Papilloma
Dr. Matthew J. Mccarty
Hematology Oncology | Hematology | Oncology
Advanced in Intraductal Papilloma
Dr. Matthew J. Mccarty
Hematology Oncology | Hematology | Oncology

University Health System, Inc.

270 Joule St, 
Alcoa, TN 
 (12.9 miles away)
865-977-6011
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Mccarty is a Hematologist Oncology specialist and a Hematologist in Alcoa, Tennessee. Dr. Mccarty is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. His top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Mccarty is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brig's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile